The association between the health of the intestines and the human body with Akkermansia muciniphila

In recent years, Akkermansia muciniphila (A. muciniphila) has gained considerable attention as an important gut microbe. In addition to endocrine and nervous system diseases, this bacterium can cause musculoskeletal and respiratory problems and other diseases. Many gastrointestinal diseases are associated with disturbances in the gut microbiota, which modulates host metabolism and immune response. A. muciniphila maintains intestinal barrier integrity, modulates the host's immune response, and improves several metabolic pathways, making this bacterium a key component in the pathogenesis of many diseases. The aim of this study was to understand the basic mechanism underlying the relationship between A. muciniphila and diseases and its interactions with hosts, establishing a causal relationship with a therapeutic supplement associated with A. muciniphila . It is well known that obesity and its related metabolic syndromes, including liver disorders and type 2 diabetes, are a worldwide epidemic that is highly linked to diet. The gut microbiota-diet interaction has been highlighted as a hot research area in treating obesity and other metabolic diseases. One of the "next-generation probiotics" for treating metabolic disorders and the inflammatory responses is A. muciniphila , which has been found to have a crucial role in metabolic diseases. A. muciniphila has been extensively studied, but little is known about its regulation in type 2 diabetes (T2D). A. muciniphila has been recognized as an important player in body metabolism and offers great promise for treating metabolic disorders associated with obesity and as a future candidate for therapeutic agents. Akkermansia muciniphila is one of the most important bacteria that colonizes the intestinal mucosa and balances metabolism, which in turn affects the treatment of obesity-related liver diseases, improving the conditions of people with type 2 diabetes and the body's metabolism. These factors make this bacterium one of the best candidates for producing new-generation probiotics. Another beneficial role of this bacterium is improving the immune system.

Authors

Institutions

Publication Details

Journal
The Microbe
Published
2025-04-26
DOI
https://doi.org/10.1016/j.microb.2025.100352
Citations
3
Primary Topic
Gut microbiota and health
Type
article
Field-Weighted Citation Impact
2.42
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The association between the health of the intestines and the human body with Akkermansia muciniphila

Hoora Mazaheri, Ava Behrouzi, Seyed Ali Sadr Tabatabaei, Hedie Yousefi Ghadim et al.
3 citations
The Microbe
Gut microbiota and health
2.42
article

The association between the health of the intestines and the human body with Akkermansia muciniphila

Hoora Mazaheri, Ava Behrouzi, Seyed Ali Sadr Tabatabaei, Hedie Yousefi Ghadim, Sara Alaei, Fatemeh Abdolvand, Farzaneh Shamsi, Yasin SarveAhrabi
article en
3 citations

Abstract

In recent years, Akkermansia muciniphila (A. muciniphila) has gained considerable attention as an important gut microbe. In addition to endocrine and nervous system diseases, this bacterium can cause musculoskeletal and respiratory problems and other diseases. Many gastrointestinal diseases are associated with disturbances in the gut microbiota, which modulates host metabolism and immune response. A. muciniphila maintains intestinal barrier integrity, modulates the host's immune response, and improves several metabolic pathways, making this bacterium a key component in the pathogenesis of many diseases. The aim of this study was to understand the basic mechanism underlying the relationship between A. muciniphila and diseases and its interactions with hosts, establishing a causal relationship with a therapeutic supplement associated with A. muciniphila . It is well known that obesity and its related metabolic syndromes, including liver disorders and type 2 diabetes, are a worldwide epidemic that is highly linked to diet. The gut microbiota-diet interaction has been highlighted as a hot research area in treating obesity and other metabolic diseases. One of the "next-generation probiotics" for treating metabolic disorders and the inflammatory responses is A. muciniphila , which has been found to have a crucial role in metabolic diseases. A. muciniphila has been extensively studied, but little is known about its regulation in type 2 diabetes (T2D). A. muciniphila has been recognized as an important player in body metabolism and offers great promise for treating metabolic disorders associated with obesity and as a future candidate for therapeutic agents. Akkermansia muciniphila is one of the most important bacteria that colonizes the intestinal mucosa and balances metabolism, which in turn affects the treatment of obesity-related liver diseases, improving the conditions of people with type 2 diabetes and the body's metabolism. These factors make this bacterium one of the best candidates for producing new-generation probiotics. Another beneficial role of this bacterium is improving the immune system.

The MicrobeVol. 7
Pasteur Institute of Iran (IR), University of Tehran (IR), Islamic Azad University Medical Branch of Tehran (IR), Islamic Azad University Central Tehran Branch (IR)
Zero hunger
Openalex Percentile: Top 12%
Gut microbiota and health
2.42
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.